Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation

Therapeutic Drug Monitoring

Volumn 28, Issue 1, 2006, Pages 62-66

  Bullock, Julie M ^a,b   Smith, Patrick F ^a,b   Booker, Brent M ^a,b   Loughner, John ^c   Capozzi, Donna ^d   McCarthy Jr , Philip L ^a   Shaw, Leslie M ^d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Busulfan; Optimal sampling model; Pharmacokinetics

Indexed keywords

BUSULFAN; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG MONITORING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PRIORITY JOURNAL; ADULT; AREA UNDER THE CURVE; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; INTESTINE ABSORPTION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BAYES THEOREM; BUSULFAN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL;

EID: 33745505699     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000180226.04137.75     Document Type: Article

References (19)

1. Sokal JE. Current concepts in the treatment of chronic myelocytic leukemia. Annu Rev Med. 1973;24:281-288.
2. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347-1353.
3. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 1998;20:543-549.
4. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55-61.
5. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31-42.
6. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet. 2000;39:155-165.
7. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225-230.
8. Lai WK, Pang CP, Law LK, et al. Routine analysis of plasma busulfan by gas chromatography-mass fragmentography. Clin Chem. 1998;44:2506-2510.
9. D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed. 1979;9:115-134.
10. Veres SM. Structure Selection of Stochastic Dynamic Systems: The Information Criterion Approach. Stochastics Monographs. Vol. 4. New York: Gordon and Breach Science Publishers; 1991:342.
11. Gibbs JP, Gooley T, Corneau B, et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood. 1999;93:4436-4440.
12. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001;28:743-751.
13. Tran HT, Madden T, Petropoulos D, et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant. 2000;26:463-470.
14. Schuler U, Schroer S, Kuhnle A, et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant. 1994;14:759-765.
15. Vaughan WP, Carey D, Perry S, et al. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant. 2002;8:619-624.
16. Hassan M, Oberg G, Bekassy AN, et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol. 1991;28:130-134.
17. Chattergoon DS, Saunders EF, Klein J, et al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children. Bone Marrow Transplant. 1997;20:347-354.
18. Balasubramanian P, Chandy M, Krishnamoorthy R, et al. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation. Bone Marrow Transplant. 2001;28:821-825.
19. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood. 1992;79:2475-2479.